AbbVie reported $64.53B in Loan Capital for its fiscal quarter ending in March of 2025.


Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Abbott USD 12.93B 194M Jun/2025
ALKERMES USD 0 0 Mar/2025
Amgen USD 53.76B 253M Jun/2025
AstraZeneca USD 25.99B 1.9B Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Eisai JPY 99.84B 9M Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
GlaxoSmithKline GBP 15.3B 1.17B Jun/2025
J&J USD 38.36B 7.7B Mar/2025
Medtronic USD 25.64B 1.66B Apr/2025
Merck USD 33.97B 484M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
Novartis USD 24.06B 2.4B Jun/2025
Pacira USD 378.1M 3.2M Jun/2025
Perrigo USD 3.62B 24.2M Jun/2025
Pfizer USD 57.5B 137M Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Roche Holding CHF 32.1B 1.94B Dec/2024
Sanofi 13.2B 211M Jun/2025
UCB EUR 2.96B 21M Dec/2024
Ultragenyx Pharmaceutical USD 782.75M 782.75M Jun/2025
United Therapeutics USD 0 0 Mar/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024
Zoetis USD 5.23B 4M Jun/2025